The Cancer Genetics and Genomics Laboratory (CGL) at BC Cancer will be commencing panel-based next generation sequencing (NGS) or “Focus Panel” testing starting May 2021. The AmpliSeq for Illumina Focus Panel enables rapid and accurate assessment of genomic variants in 52 genes with known clinical relevance in solid tumors. Additional details of the test and indications that qualify for this testing can be found in the memo below.
Uncategorized
MYD88 L265P testing
The Cancer Genetics and Genomics Laboratory is offering a new test that interrogates the myeloid differentiation primary response 88 (MYD88) gene to detect the L265P mutation. MYD88 L265P is identified in approximately 90% of confirmed lymphoplasmacytic lymphoma (LPL) cases and therefore increases the likelihood for a MYD88 related LPL diagnosis. Additional details of the test can be found in the memo below.
New FLT3 ITD and TKD test
The Cancer Genetics and Genomics Laboratory (CGL) at BC Cancer has improved testing for clinically relevant variants in the Fms-related tyrosine kinase 3 gene (FLT3). Further details on the changes to testing can be found in the memo below.
KIT D816V/F – New test
The Cancer Genetics and Genomics Laboratory’s (CGL) at BC Cancer has developed a new more sensitive test for detection of the KIT D816V and D816F mutations. Additional details on how the test has changed can be found in the below memo.